Skip to main content

Advertisement

Open Peer Review Reports for: A randomized multi-center phase II trial of the angiogenesis inhibitor Cilengitide (EMD 121974) and gemcitabine compared with gemcitabine alone in advanced unresectable pancreatic cancer

Back to article

Pre-publication versions of this article are available by contacting info@biomedcentral.com.

Original Submission
20 Mar 2006 Submitted Original manuscript
29 Mar 2006 Reviewed Reviewer Report - Andrew Ko
2 Apr 2006 Reviewed Reviewer Report - Henry Xiong
14 Apr 2006 Reviewed Reviewer Report - Michele Reni
10 May 2006 Author responded Author comments - Jorg Kleeff
Resubmission - Version 2
10 May 2006 Submitted Manuscript version 2
25 May 2006 Reviewed Reviewer Report - Andrew Ko
25 May 2006 Reviewed Reviewer Report - Andrew Willan
31 May 2006 Reviewed Reviewer Report - Michele Reni
10 Jun 2006 Reviewed Reviewer Report - Henry Xiong
28 Jul 2006 Author responded Author comments - Jorg Kleeff
Resubmission - Version 3
28 Jul 2006 Submitted Manuscript version 3
25 Sep 2006 Reviewed Reviewer Report - Andrew Willan
6 Nov 2006 Author responded Author comments - Jorg Kleeff
Resubmission - Version 4
6 Nov 2006 Submitted Manuscript version 4
7 Dec 2006 Reviewed Reviewer Report - Andrew Willan
8 Dec 2006 Author responded Author comments - Jorg Kleeff
Resubmission - Version 5
8 Dec 2006 Submitted Manuscript version 5
8 Dec 2006 Author responded Author comments - Jorg Kleeff
Resubmission - Version 6
8 Dec 2006 Submitted Manuscript version 6
Publishing
11 Dec 2006 Editorially accepted
11 Dec 2006 Article published 10.1186/1471-2407-6-285

How does Open Peer Review work?

Open peer review is a system where authors know who the reviewers are, and the reviewers know who the authors are. If the manuscript is accepted, the named reviewer reports are published alongside the article. Pre-publication versions of the article are available by contacting info@biomedcentral.com.

You can find further information about the peer review system here.

Advertisement